摘要
目的:探讨芪冬益心口服液治疗冠心病经皮冠状动脉介入(PCI)术后伴慢性失眠的临床疗效。方法:选取2018年3月至2019年8月定陶区人民医院收治的PCI术后患者60例作为研究对象,随机分为对照组30例和观察组30例。对照组予以右佐匹克隆片,观察组则使用芪冬益心口服液治疗,观察1年。以西雅图心绞痛调查量表(SAQ)、匹兹堡睡眠指数(PSQI)为评测指标,比较2组患者治疗前后SAQ、PSQI评分变化。结果:治疗前,2组SAQ、PSQI评分差异无统计学意义(P>0.05);治疗后,观察组SAQ评分优于对照组(P<0.05),观察组PSQI评分低于对照组(P<0.05)。结论:芪冬益心口服液治疗冠心病PCI术后伴慢性失眠患者效果显著,能明显改善心绞痛及睡眠障碍的症状。
Objective:To investigate the clinical efficacy of Qidong Yixin oral liquid in the treatment of chronic insomnia with coronary heart disease after percutaneous coronary intervention(PCI).Methods:A total of 60 patients after PCI who were admitted to the People′s Hospital of Dingtao District from March 2018 to August 2019 were enrolled.According to admission order,they were divided into control group(30 cases)and observation group(30 cases).The control group was treated with dexzopiclone tablets as needed,while observation group was treated with QidongYixin oral liquid for 1 year.The changes of SAQ and PSQI scores before and after treatment were compared between the two groups.Results:Before treatment,there were no significant differences in SAQ and PSQI scores between the two groups(P>0.05).After treatment,SAQ score in observation group was better than that in control group(P<0.05),and PSQI score was lower than that in control group(P<0.05).Conclusion:The curative effect of QidongYixin oral liquid is significant on chronic insomnia with coronary heart disease after PCI,which can significantly improve angina and sleep disorders.
作者
刘仁义
LIU Renyi(Department of Cardiovascular Medicine,People′s Hospital of Dingtao District,Heze,Shandong Province,Heze 274100,China)
出处
《世界睡眠医学杂志》
2021年第3期403-404,共2页
World Journal of Sleep Medicine
关键词
芪冬益心口服液
冠心病
慢性失眠
Qidong Yixin oral liquid
Coronary heart disease
Chronic insomnia